John Wey
Child & Adolescent Psychiatry · Yakima, WANPI 1336274943
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 204 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,228 and has fallen 66.8% since, to $407 in 2025. Among child & adolescent psychiatry clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 204 payments — averaging $25.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$989
- Supernus Pharmaceuticals, Inc.$983
- Otsuka America Pharmaceutical, Inc.$726
- Neurocrine Biosciences, Inc.$517
- AbbVie$380
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$370
- plus $1K from 12 others
What the payments were for
- Food & beverage$5,230100%
- Education$30%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 33 | $989 |
| Supernus Pharmaceuticals, Inc. | 51 | $983 |
| Otsuka America Pharmaceutical, Inc. | 27 | $726 |
| Neurocrine Biosciences, Inc. | 13 | $517 |
| AbbVie(2 entities) | 13 | $380 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 19 | $370 |
| Sunovion Pharmaceuticals Inc. | 10 | $269 |
| Alkermes, Inc. | 8 | $260 |
| Lundbeck LLC | 9 | $211 |
| Corium, LLC | 6 | $142 |
| Johnson & Johnson | 3 | $134 |
| Jazz Pharmaceuticals Inc. | 3 | $69 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $54 |
| Vanda Pharmaceuticals Inc. | 1 | $31 |
| Indivior Inc. | 1 | $29 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $26 |
| Shire North American Group Inc | 1 | $22 |
| Neuronetics, Inc. | 3 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,234 in reported general payments places this provider in the 95th percentile of 45 child & adolescent psychiatry providers in Washington.
See all child & adolescent psychiatry providers in Washington →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Methylphenidate Hcl | 11 | $708 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 13 | $335 |
| Bupropion XlBupropion Hcl | 20 | $214 |
Paid to pharmacies, not to this prescriber.
Other child & adolescent psychiatry in Yakima
- Jana SpasovskiYakima$122
- John OmalleyYakima$37
- Kris PetersonLakewood$105K
- Bryan KingSeattle$5K
- Daniel LamVancouver$3K
- Dirk DhosscheSpokane$2K
- Tatjana DereticBellevue$719
- Thomas SemperSeattle$685
- Kenneth KingRedmond$632
- Julia MoorePort Townsend$626
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.